HEMOPATIAS MALIGNAS - Instituto de Oncología Ángel H. Roffo

366 PAUTAS DE DIAGNOSTICO Y TRATAMIENTO / INSTITUTO ANGEL H. ROFFO
FASE B (ciclos 2, 4, 6 y 8)
RITUXIMAB 375 mg/m 2 IV Día 0
METOTREXATE 200 mg/m 2 IV (en 2 hs) Día 1, seguido por
METOTREXATE 800 mg/m 2 IV (en 22 hs) Día 1
CITARABINA (*) 3000 mg/m 2 IV (en 2 hs) c/12 Días 2 y 3 (4 dosis)
LEUCOVORINA 50 mgIV c/6 hs empezando 12 hs después del
final del goteo de MTX x 2 dosis
LEUCOVORINA 15 mg VO c/6 hs x 8 dosis
FILGRASTIMhasta 10 mcrg/kg/día (usualmente se usa 5 mcrg/kg/día) a partir del día 5 hasta polimorfonucleares
> de 3000/mm 3
Gotas oftálmicas con dexametasona
Profilaxis con FLUCONAZOL 100 mg VO, LEVOFLOXACINA 500 mg VO x 10 días (comenzando 24-36 hs luego de
la última dosis de CITARABINA)
Ciclos cada 21 días
(*) Dosis de CITARABINA se ajusta en pacientes mayores de 60 años a partir del día 5 hasta polimorfonucleares
> de 3000/mm 3
PROFILAXIS DEL SNC:
TIT en cada ciclo de QT
BIBLIOGRAFIA
56. Howard OM, Gribben JG, Neuberg DS, et
al. Rituximab and CHOP induction therapy for
newly diagnosed mantle-cell lymphoma:
molecular complete responses are not predictive
of progression-free survival. J Clin Oncol 2002;
20: 1288-1294.
57.Romaguera JE, Fayad L, Rodriguez MA, et
al. Rituximab plus hypercvad (R-HCVAD)
alternating with rituximab plus high-dose
methotrexate-cytarabine (R-M/A) in untreated
mantle cell lymphoma (MCL): prolonges followup
confirms high rates of failure-free survival
(FFS) and overall survival (OS). Program and
abstracts of the 46th Annual Meeting of the
American Society of Hematology; December 4-7,
2004; San Diego, California. Abstract 128. Blood
2004; 104.
58. Romaguera J.E., Khouri I.F., Kantarjian
H.M., et al. Untreated aggressive mantle cell
lymphoma: results with intensive chemotherapy
without stem cell transplant in elderly patients.
Leuk Lymphoma 2000; 39: 77-85.
59. Lenz G, Dreyling M, Hoster E, et al.
Inmunochemotherapy with rituximab and
cyclophosphamide, doxorrubicin, vincristine, and
prednisone significantly improves response and
time to treatment failure, but non long-term
outcome in patients with previously untreated
mantle cell lymphoma: results of a prospective
randomized trial of the German Low Grade
Lymphoma Study Group (GLSG). J Clin Oncol
2005; 23: 1984-1992.
60. Dreyling M, Lenz G, Hoster E, et al. Early
consolidation by myeloablative
radiochemotherapy followed by autologous stem
cell transplantation in first remission significantly
prolongs progression-free survival in mantle-cell
lymphoma: results of a prospective randomized
trial of the European MCL Network. Blood 2005;
105: 2677-2684.
61. O´Connor OA, Wright J, Moslowitx C, et
al. Phase II clinical experience with the novel
proteasome inhibitor bortezomib in patients with
indolent non Hodgkin´s lymphoma and mantle
cell lymphoma. J Clin Oncol 2005; 23: 676-684.
62. Goy A., Younes A, Mc Laughlin P, et al.
Phase II study of proteasome inhibitor bortezomib
in relapsed or refractory B-cell non Hodgkin´s
lymphoma. J Clin Oncol 2005; 23: 667-675.
63. Fisher R, Bernstein S, Kahl B, Djulbegovic
B, et al, and the PINNACLE Study Team.
Estudio PINNACLE de Bortezomib en MCL
recaído y refactario. Journal of Clin Oncol 2006;
24: 4867-4874.